Core Viewpoint - The company has officially launched a Phase III clinical trial for its proprietary product, Keguan Liyan Oral Solution, aimed at treating acute pharyngitis caused by external wind-heat syndrome [1] Group 1: Product Information - Keguan Liyan Oral Solution received its new drug certificate and production approval in 1997, making it a unique product of Wanglaoji Pharmaceutical [1] - The product is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China and is known for its effects of dispelling wind, clearing heat, and detoxifying, primarily used for colds associated with external wind-heat invasion [1] Group 2: Clinical Trial Details - Wanglaoji Pharmaceutical obtained the clinical trial approval notice from the National Medical Products Administration in February 2024, allowing the company to conduct confirmatory clinical trials for acute pharyngitis [1] - The Phase III clinical trial has recently been officially initiated by Wanglaoji Pharmaceutical [1]

Core Viewpoint - The company announced the initiation of a Phase III clinical trial for its product, Keguanli Yan Oral Liquid, aimed at treating acute pharyngitis associated with external wind-heat syndrome [1] Group 1 - The clinical trial was organized by the company's subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd. [1] - The trial is a significant step in the development of the company's product portfolio in the pharmaceutical sector [1]

Core Viewpoint - The company announced the initiation of a Phase III clinical trial for its proprietary product, Keguanli Yan Oral Liquid, aimed at treating acute pharyngitis caused by external wind-heat syndrome [1] Group 1: Product Information - Keguanli Yan Oral Liquid received its new drug certificate and production approval in 1997, making it a unique product of Wanglaoji Pharmaceutical [1] - The product is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China and is known for its effects of dispelling wind, clearing heat, and detoxifying, primarily used for cold symptoms associated with wind-heat invasion [1] Group 2: Clinical Trial Details - Wanglaoji Pharmaceutical obtained the clinical trial approval notice from the National Medical Products Administration in February 2024, allowing the company to conduct confirmatory clinical trials for acute pharyngitis [1] - The Phase III clinical trial has recently been officially launched by Wanglaoji Pharmaceutical [1]

关于子公司药物进入 III 期临床试验的公告 证券代码：600332 证券简称：白云山 公告编号：2025－076 广州白云山医药集团股份有限公司 王老吉药业2024年克感利咽口服液的销售额为人民币1,828.52万元，除王老吉药 业生产的克感利咽口服液外，中国境内上市的克感利咽颗粒的生产厂家有葵花药业集 1 团（襄阳）隆中有限公司、临江市宏大药业有限公司等。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"公司"）子公司广州王老吉药业股份有限 公司（"王老吉药业"）于近日召开克感利咽口服液治疗急性咽炎（外感风热证）的 III期临床试验启动会，该III期临床试验项目正式启动。现将相关情况公告如下： 一、克感利咽口服液的基本情况 药物名称：克感利咽口服液 剂型：合剂 规格：10 mL/支 注册分类：2.3类新药 二、克感利咽口服液的其他情况 克感利咽口服液于1997年获得新药证书和生产批件，是王老吉药业独家品种，收 载于《中华人民共和国药典》2025年版一部，具有疏风清热，解毒利咽作用，主要用 ...

海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司藥物進入III期臨床試驗的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年10月17日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 剂型：合剂 证券代码：600332 证券简称：白云山 公告编号：2025－076 广州白云山医药集团股份有限公司 关于子公司药物进入 III 期临床试验的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白 ...

Core Viewpoint - Guangzhou Pharmaceutical Holdings Limited's subsidiary, Wanglaoji Pharmaceutical, has officially launched a Phase III clinical trial for its product, Keguanli Throat Oral Solution, aimed at treating acute pharyngitis [1] Group 1: Clinical Trial Details - The Phase III clinical trial for Keguanli Throat Oral Solution was initiated recently [1] - The product received its new drug certificate and production approval in 1997 and is listed in the 2025 edition of the Pharmacopoeia of the People's Republic of China [1] - The solution is indicated for symptoms related to wind-heat invasion and internal heat disturbance, primarily used for colds [1] Group 2: Regulatory Approvals - Wanglaoji Pharmaceutical obtained the clinical trial approval notice from the National Medical Products Administration in February 2024 [1] - The approval allows the company to conduct confirmatory clinical trials for acute pharyngitis [1]

Core Viewpoint - The announcement indicates that Guangzhou Wanglaoji Pharmaceutical Co., Ltd., a subsidiary of Baiyunshan, has officially launched the Phase III clinical trial for the drug Kegang Liyan Oral Liquid, aimed at treating acute pharyngitis [1] Group 1: Product Details - Kegang Liyan Oral Liquid is classified as a Class 2.3 new drug, with a specification of 10 mL per bottle, designed to dispel wind, clear heat, and detoxify [1] - The projected sales revenue for Kegang Liyan Oral Liquid in 2024 is estimated at RMB 18.2852 million [1] Group 2: Financial Investment - As of September 2025, the project has incurred research and development expenses of approximately RMB 18.1542 million (unaudited) [1]

王老吉和加多宝又"打起来了"！ 从国内打到海外，偌大的凉茶江湖，这对"宿敌"的恩怨何时休？ 01，王老吉加多宝再交火 近日，王老吉和加多宝多轮隔空交火引发关注，伴随着#王老吉发文有病去医院有事找法院#、 #王老吉先上火了#等相关话题冲上热搜，最高2名，并拿下实时热度第1 ，至此，"凉茶双雄"新一轮缠 斗全面爆发 为了大家更好地厘清事件来龙去脉，笔者照例为吃瓜群众梳理一下时间线： 9月29日，加多宝在其官网发布公告称维权告捷，其关联的Multi Access Limited（万捷有限公司）在加 拿大联邦法院及欧盟普通法院的多起诉讼中，接连取得得大胜利，成功捍卫"王老吉"海外系列商标的合 法权益，标志着加多宝品牌国际化战略迈上新台阶。 | | 加多寶擁有有效王老吉商標註冊的國家和地区 | 加多冒拥有的王老吉主要面临 | | | --- | --- | --- | --- | | 北美洲 | ● 科威特 | | | | ● 加拿大 | नेर सेव | | 壬老言 | | 哥斯弹婴加 | 黎巴嫩 | | | | 古巴 | 中國演唱 | | | | 巴拿馬 | 馬來西亞 | | | | 美國 | 尼泊爾 | | | ...

Core Viewpoint - The ongoing rivalry between Wanglaoji and Jia Duo Bao, two major herbal tea brands in China, has escalated from domestic disputes to international markets, highlighting the challenges and strategic choices both companies face in their globalization efforts [1][2][3]. Group 1: Historical Context - The conflict between Wanglaoji and Jia Duo Bao dates back over a decade, marked by the "red can dispute," which has become a classic case in Chinese business history [1]. - Recent tensions reignited on September 30, when Jia Duo Bao claimed victory in international trademark disputes, asserting ownership of the "Wanglaoji" trademark in over 60 countries [3][4]. - Wanglaoji responded by accusing Jia Duo Bao of maliciously registering trademarks abroad and announced its own trademark registrations in over 100 countries by September 2025 [3][4]. Group 2: Strategic Moves - Both companies are targeting international markets as domestic growth stagnates, with Wanglaoji and Jia Duo Bao recognizing the necessity of expanding overseas to seek new growth opportunities [2][10]. - Wanglaoji has been actively promoting its brand internationally since 2013, establishing a presence in the U.S. and launching its international brand "WALOVI" in 2023 [9][10]. - Jia Duo Bao has also made strides in international markets, establishing production bases in Malaysia and signing agreements for further expansion [9]. Group 3: Market Dynamics - The herbal tea market in China has shown signs of saturation, with retail sales fluctuating since 2016 and a growth rate of approximately 20% over the past decade [10][13]. - Both companies face competition from emerging beverage brands and traditional tea products, which have diversified consumer preferences and fragmented the market [14][15]. - The global plant-based beverage market is experiencing significant growth, with a compound annual growth rate of nearly 10% from 2019 to 2024, presenting opportunities for both brands [13]. Group 4: Internal Challenges - The prolonged legal battles between Wanglaoji and Jia Duo Bao have diverted resources and attention from product innovation and market expansion, leading to stagnation in their respective growth strategies [17][18]. - Both companies are struggling to diversify beyond the herbal tea category, which limits their potential in international markets [17]. - A collaborative approach to promote "Chinese herbal tea" as a category could benefit both companies and enhance their global presence, rather than continuing their competitive rivalry [17][18].

Core Viewpoint - The ongoing trademark dispute between Wanglaoji and Jia Duo Bao highlights the complexities of intellectual property rights as Chinese brands expand internationally, with both companies asserting their claims over the "Wanglaoji" trademark in various global markets [1][3][6]. Group 1: Trademark Dispute Developments - On September 30, Jia Duo Bao announced victories in multiple lawsuits in Canada and the EU, claiming to protect its overseas trademark rights for "Wanglaoji," asserting ownership since the early 2000s and registration in over 60 countries [1]. - Wanglaoji quickly countered, accusing Jia Duo Bao of misleading the public and revealing that it has initiated trademark protection actions in 21 countries, with some jurisdictions already ruling in favor of Wanglaoji [2]. - The trademark conflict stems from over two decades of partnership and subsequent legal battles, with a recent ruling ordering Jia Duo Bao to pay Wanglaoji 317 million yuan for trademark infringement [3]. Group 2: Market Context and Growth Challenges - Despite dominating the domestic herbal tea market, both companies face stagnation as new beverage categories divert consumer interest, prompting a focus on international expansion [4]. - Wanglaoji has seen its overseas market grow 6.5 times over the past decade, with a compound annual growth rate exceeding 25%, and has registered its trademarks in over 100 countries [4]. - Both companies are establishing local production bases to enhance their market presence, with Wanglaoji partnering with local firms to build an 800 million can annual capacity in Malaysia [4]. Group 3: Intellectual Property Challenges - The trademark battle reflects broader challenges faced by Chinese companies in protecting their intellectual property abroad, with over 2,000 instances of trademark registration disputes reported since the 1980s, leading to significant asset losses [6][7]. - The regional nature of trademark laws complicates enforcement, as different jurisdictions have varying principles regarding trademark rights, impacting both companies' strategies [6][7]. - The difficulty in proving malicious registration adds to the complexity, as companies must gather evidence across borders, which can be costly and time-consuming [7]. Group 4: Strategic Recommendations - Experts suggest that traditional brands must integrate intellectual property into their core strategies, emphasizing the importance of comprehensive planning and proactive trademark registration [2][8]. - Companies are advised to enhance their brand narratives and cultural heritage to secure broader trademark protections and avoid potential conflicts in international markets [8]. - The case serves as a cautionary tale for Chinese enterprises aiming for global expansion, underscoring the necessity of clarifying trademark rights before entering new markets [9].